Skip to main content

Advertisement

You are viewing the new article page. Let us know what you think. Return to old version

Poster presentation | Open | Published:

Leukemia/lymphoma development in IL-15-deficient TCR-transgenic mice

Sporadic mouse tumor models are valuable tools to understand disease development and treatment efficacies. Here we show that a transgenic T cell receptor expression predisposes mice to leukemia/lymphoma development. Leukemia/lymphoma precursors expressed low amounts of MHC class I and were deleted by NK cells in immunocompetent mice resulting in increased tumor frequency under NK cell absence. Leukemias/lymphomas were clonal and regrow after transfers into NK cell-deficient hosts. Phenotypically, most leukemias/lymphomas were positive for CD3 and CD8, and all expressed high levels of the co-stimulatory molecules PD1, ICOS and CD28 as well as of CD30 resembling the phenotype of immature CD8 single-positive thymocytes. Half of the leukemias/lymphomas harbored Notch1 mutations. Dendritic cells appear to have an auxiliary role in leukemia/lymphomagenesis since their deletion caused decreased tumor growth. The study of leukemias/lymphomas in IL-15-deficient TCR-transgenic mice may help to further understand T cell lymphomagenesis, the role of lymphoma environment, and may be useful to design and test treatments.

Author information

Correspondence to Sigrid Dubois.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Mouse Tumor
  • Test Treatment
  • Mouse Tumor Model
  • Immunocompetent Mouse
  • Tumor Frequency